Objectives: Prophylactic levetiracetam is currently used in ~40% of patients with intracerebral hemorrhage, and the potential impact of levetircetam on health-related quality of life is unknown. We tested the hypothesis that prophylactic levetiracetam is independently associated with differences in cognitive function healthrelated quality of life. Design: Patients with intracerebral hemorrhage were enrolled in a prospective cohort study. We performed mixed models for T-scores of health-related quality of life, referenced to the U.S. population at 50 ± 10, accounting for severity of injury and time to follow-up. Setting: Academic medical center. Patients: One-hundred forty-two survivors of intracerebral hemorrhage. Interventions: None. Measurements and Main Results: T-scores of Neuro-Quality of Life Cognitive Function v2.0 was the primary outcome, whereas Neuro-Quality of Life Mobility v1.0 and modified Rankin Scale (a global functional scale) were secondary measures. We prospectively documented if prophylactic levetiracetam was administered and retrieved administration data from the electronic health record. Patients who received prophylactic levetiracetam had worse cognitive function health-related quality of life (T-score 5.1 points lower; p = 0.01) after adjustment for age (p = 0.3), National Institutes of Health Stroke Scale (p < 0.000001), lobar hematoma (p = 0.9), and time of assessment; statistical models controlling for prophylactic levetiracetam and the Intracerebral Hemorrhage Score, a global measure of intracerebral hemorrhage severity, yielded similar results. Lower T-scores of cognitive function healthrelated quality of life at 3 months were correlated with more total levetiracetam dosage (p = 0.01) and more administered doses of levetiracetam in the hospital (p = 0.03). Patients who received prophylactic levetiracetam were more likely to have a lobar hematoma (27/38 vs 19/104; p < 0.001), undergo electroencephalography monitoring (15/38 vs 21/104; p = 0.02), but not more likely to have clinical seizures (4/38 vs 7/104; p = 0.5). Levetiracetam was not independently associated with the modified Rankin Scale scores or mobility health-related quality of life (p > 0.1). Conclusions: Prophylactic levetiracetam was independently associated with lower cognitive function health-related quality of life at follow-up after intracerebral hemorrhage.
S
eizures are a feared complication of intracerebral hemorrhage (ICH), occurring in 10-25% of patients acutely (1) , and in the years after ICH (2) . Seizures may lead to midline shift (3), cerebral ischemia, and worse patient outcomes. Thus, treatment with prophylactic seizure medications is a reasonable therapeutic strategy if the treatment carries a low risk of complications and the patient has an elevated risk of seizures (e.g., elevated Cortical involvement, Age, Volume, Early seizures score [2, a composite with 1 point each for lobar hematoma location, hematoma volume greater than 10 mL, age less than 65 years, and a seizure within 7 d of ICH onset).
Prophylactic phenytoin was recommended by guidelines in 1999 and 2007 (4, 5) . However, in 2009, two independent reports noted that phenytoin use was independently associated with significant complications, particularly fever, and worse functional outcomes at follow-up (6, 7) . This led to a revised guideline recommendation in 2010 to avoid prophylactic seizure medications (8) .
Since the revised guideline recommendation, clinicians have switched from administering phenytoin to levetiracetam (9, 10) , which has fewer acute adverse events (11) . Although likely to be safer than phenytoin, levetiracetam may also have side effects that impair health-related quality of life (HRQoL), such as altered cognitive function (e.g., trouble with memory) (12) , and as noted in its package insert. Reductions in HRQoL, even if meaningful to patients, might not be detected by global, ordinal outcome scales, such as the modified Rankin Scale (mRS), a commonly used outcome measure for patients with ICH; a recent publication found no effect of prophylactic levetiracetam on the mRS (9) . Further, cognitive side effects may manifest as delirium symptoms, which is predictive of worse cognitive function HRQoL after ICH (13) (14) (15) (16) . We hypothesized that prophylactic levetiracetam would be associated with lower cognitive function HRQoL after ICH.
MATERIALS AND METHODS

Patients
Patients with spontaneous ICH were prospectively identified on hospital admission as previously noted (17) . Demographic information, medical history, home medications, standardized clinical assessments of severity (e.g., National Institutes of Health [NIH] Stroke Scale, a standardized neurologic examination, and the ICH Score, a composite of age, hematoma volume, location and level of consciousness), imaging data, medical management variables, and medical complications, including the number of days with a core temperature at least 100.4 F within 14 days of ICH and ventilator-free days within 14 days of ICH onset, were prospectively recorded in a study database.
Severity of Injury
Acute Physiology and Chronic Health Evaluation (APACHE) IV scores (18) are automatically calculated from data in the electronic health record and retrieved for analysis.
EEG Monitoring
The ICU protocol stipulated that all patients with ICH and reduced consciousness (e.g., not arousable to voice and following commands) undergo continuous electroencephalography (EEG) monitoring for at least 24 hours, which is reviewed at least bid by a certified electroencephalographer. Consideration of discontinuing EEG monitoring after 24 hours is determined by mutual agreement by the electroencephalographer and neurointensivist based upon the likelihood of discovering subclinical seizures.
Delirium
Delirium symptoms were assessed with the Confusion Assessment Method for the ICU as documented in the electronic health record, as previously described (15) . Methods for identifying delirium in patients with neurologic disease have been previously described as new alterations in consciousness compared with the baseline of consciousness on hospital admission (16) .
Medication Dosing
We electronically retrieved each individual administered dose of levetiracetam, as previously described for phenytoin (6) . We did not determine levetiracetam use at follow-up as it was not feasible to perform medication reconciliation comparable with admission, and patients may not wish to divulge changes in seizure medication because this may affect their legal status to operate a motor vehicle (19) . We retrieved data on each administered dose of benzodiazepines.
Ethical Approval
The proposal was approved by the Institutional Review Board. Patients provided consent for data acquisition. If the patient could not be consented due to neurologic injury, a legally authorized representative was asked to provide consent.
HRQoL Assessment
As previously reported (15, 20) , we assessed HRQoL outcomes with Neuro-Quality of Life (QOL), which are validated, standardized tests in specific domains of HRQoL, such as cognitive function v2.0 (e.g., ability to manage finances, concentration, memory) and mobility v1.0 (e.g., ability to get around, walking, daily activities). Neuro-QOL is similar to the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) and was validated with proxy report as part of its development (21) . We included data from patients from May 2011 to October 2016 who survived to posthospitalization follow-up. We obtained HRQoL at 1, 3, and 12 months after ICH onset, as previously described (15) . Results are reported in T-scores normalized to the U.S. general population at 50 ± 10, that is, the average person in the United States will have a score about 50. As noted elsewhere, 0.5 sd, 5 points on the T-score, half a sd, is considered a meaningful difference (22) . We also obtained outcomes with the mRS as previously described, using a validated questionnaire (23) .
Statistical Analysis
Normally distributed data (e.g., age) are reported as mean ± sd. Nonnormally distributed data (e.g., days with fever) are reported as median (Q1-Q3) and were compared with Kolmogorov-Smirnov test. Categorical data (e.g., categorical use of levetiracetam) are reported as proportions and were compared using a chi-square or Fisher exact test as appropriate. Correlations of duration of levetiracetam use and T-scores of cognitive function HRQoL were performed with Spearman coefficient. We performed mixed models, as previously described, controlling for time of assessment (1, 3, and 12 mo after ICH), age, and NIH Stroke Scale score (as previously reported) (15) , with the use of prophylactic levetiracetam as the variable of interest. Alternatively, controlled for ICH Score instead of age and NIH Stroke Scale because age and severity of injury are incorporated into the ICH Score. Statistical tests were two sided. Statistical analyses were calculated with standard commercial software (NCSS 9; NCSS, Kaysville, UT). The analysis was overseen and directed by Neuro-QOL and NIH PROMIS Statistical Center, which were not involved in data collection (J.B., D.C.).
RESULTS
Of 394 patients with ICH, 122 died, 91 were lost to follow-up, 24 declined permission, and 15 did not provide HRQoL, leaving 142 in whom we assessed HRQoL data. Demographics for enrolled patients are shown in Table 1 .
Characteristics of patients who received prophylactic levetiracetam or not are shown in Novel oral anticoagulant prior to ICH, n (%)
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Moderate disability or worse prior to ICH, n (%) 14 (9) ICH = intracerebral hemorrhage.
patients (4%) with nonconvulsive (subclinical) seizures discovered on EEG monitoring, five of whom received levetiracetam prophylaxis (p = 0.006). In mixed models, levetiracetam prophylaxis was independently associated with lower T-scores in cognitive function HRQoL (5.1 points; p = 0.01) after correction for age (p = 0.3) and NIH Stroke Scale score (p < 0.000001). There were similar results (levetiracetam prophylaxis associated with a worse T-score by 5.3 points; p = 0.009) after correcting for the ICH score (p = 0.000001) (Fig. 1) . Additionally, controlling for lobar hematoma location or nonconvulsive seizures did not significantly add to the model (p > 0.2) and did not meaningfully change the results. In unadjusted analyses, T-scores of cognitive function HRQoL were more different at 1 month (32.1 ± 14 vs 43.7 ± 12.7; p = 0.04) but were not different at 3 months (36.8 ± 10.9 vs 37.8 ± 8.1; p > 0.2) or 12 months (37.6 ± 12.6 vs 26.3 ± 13.5; p > 0.2).
Prior to admission for ICH, there were two patients who had a history of clinical seizure and two additional patients with a clinical history of dementia. Removing these patients from the analysis, or patients who had a clinical seizure in the hospital, did not meaningfully affect the results.
There were no associations between the administration of levetiracetam and mobility HRQoL (p > 0.1) or the mRS (p > 0.1).
DISCUSSION
We confirmed the hypothesis that prophylactic levetiracetam, administered in the hospitalization for ICH, was independently associated with lower cognitive function HRQoL at follow-up after ICH. These data may be important for the management of ICH, because ~40% of ICH patients in the United States receive prophylactic levetiracetam (9, 10), higher than the occurrence rate of clinical seizures. If prophylactic levetiracetam, even if potentially efficacious for preventing seizures, may worsen cognitive function HRQoL, these findings potentially impact many patients with ICH. History of diabetes, n (%) 8 (21) 18 (17) 0.6
History of ischemic stroke, n (%) 6 (16) 15 (14) 0.8
History of coronary artery disease, n (%) 3 (8) 7 (7) 0.8
History of atrial fibrillation, n (%) 4 (10) 5 (5) Patients with ICH do not indiscriminately receive levetiracetam, rather treatment is generally given to patients at elevated risk for seizures due to lobar hematoma location (3, 24) and a correspondingly higher CAVE score. Controlling for lobar hematoma in statistical models was not statistically significant and did not change the association of prophylactic levetiracetam with worse cognitive function HRQoL. In other words, levetiracetam is already administered to patients who have known risk factors for seizures, and levetiracetam may worsen HRQoL in this subgroup.
Levetiracetam was administered at a relatively low dose of 500 mg bid in this cohort for a median of approximately 1 week after ICH, and even this relatively modest dose and duration of treatment were associated with lower cognitive function HRQoL. These data do not support the assertion that only longstanding therapy is responsible for lower cognitive function HRQoL; the positive correlation between the duration of treatment and lower cognitive function HRQoL suggests that longer treatment might lead to worse cognitive function HRQoL. The association between administration of seizure medication and lower subsequent measures of cognitive function is consistent with levetiracetam's package insert and the known association of prophylactic phenytoin administration and lower subsequent measures of cognitive function after subarachnoid hemorrhage (ruptured brain aneurysm) (25) and stroke generally (26) . Conversely, levetiracetam has been associated with neuroprotection, particularly in animal models of traumatic brain injury (27) (28) (29) . The effects of levetiracetam on outcomes require further study and may vary between neurologic conditions. It is not clear from these data if levetiracetam is effective for preventing clinical seizures after ICH. A separate investigation suggested that levetiracetam is not effective for preventing seizures in patients with aneurysmal subarachnoid hemorrhage (30) . Levetiracetam prophylaxis was more common in patients who were subsequently discovered to have nonconvulsive (subclinical) seizures in this cohort, likely representing a correct assessment of high seizure risk by clinicians and the known predictions of the CAVE score.
Delirium is common in patients with ischemic stroke (31), as well as ICH (16), and predicts worse cognitive function HRQoL (13, 15) . However, we did not find an association between prophylactic levetiracetam and delirium. These data suggest that the association of levetiracetam and worse cognitive function HRQoL is unlikely to be mediated by delirium.
Previous investigations have found that levetiracetam is better tolerated than phenytoin (11) , which was associated with more fever and worse outcomes after ICH (6) . Following the publication of data on the adverse drug effects on phenytoin after ICH (6, 7), clinicians switched from phenytoin to levetiracetam (9, 10), rather than abstaining from seizure medications generally. These data do not support switching from levetiracetam to another seizure medication. Indeed, levetiracetam is likely to be safer and better tolerated than other seizure medications available for parenteral use (e.g., valproate, which can lead to hepatic toxicity and coagulopathy, or lacosamide, which may lead to heart block).
There are limitations to this study. We did not have an adjudicated process for determining whether a seizure occurred after hospital discharge, and patients may not be forthcoming in reporting a seizure for fear of losing the privilege of driving a motor vehicle for several months (19) . One would expect that patients who did not receive prophylactic levetiracetam would be more likely to have a seizure after hospital discharge and have lower HRQoL from a seizure (32) , which would bias our results toward finding no effect of levetiracetam, rather than the association of prophylactic levetiracetam with lower HRQoL. We have previously noted that HRQoL outcomes are less likely to be obtained in patients who are neurologically devastated or dead (33) , so these results are most applicable to patients with ICH who are likely to survive (ICH Score 0-2) with no deficit to a moderate neurologic deficit (e.g., mRS 0-4) and a CAVE score of 1 or greater. The importance of this bias in obtaining HRQoL may be attenuated because levetiracetam is not plausibly associated with mortality. We measured patient-reported HRQoL, not objective cognitive function, which would require in-person follow-up, and might make results less generalizable. However, patient-reported deficits in cognitive are typically accurate for identifying objective cognitive deficits (34) . Objective cognitive function assessments provide an opportunity for future research. Although medication reconciliation is performed on hospital admission (35), we do not have a validated medication reconciliation performed at follow-up, such as pill counts. Uncertainty of later levetiracetam use would be likely to bias our results toward the null hypothesis of no association between levetiracetam and HRQoL at follow-up. 
CONCLUSIONS
Prophylactic administration of levetiracetam during hospitalization for ICH was independently associated with lower cognitive function HRQoL at follow-up. These data suggest that prophylactic levetiracetam may have persistent effects on cognitive function HRQoL. Further research might clarify the potential benefits of prophylactic seizure medications in patients with ICH weighed against potential reductions in HRQoL from prophylactic seizure medications.
